[6-K] Denison Mines Corp Current Report (Foreign Issuer)
Champions Oncology (CSBR) filed an 8-K disclosing a leadership change effective 25 Aug 2025. Director Robert Brainin, 54, will become Chief Executive Officer while retaining his board seat. Brainin brings 25+ years of life-science experience, most recently as Chief Business Officer & EVP at Veracyte, and previously held senior roles at Genuity Science, Illumina, Thermo Fisher and Life Technologies.
Key employment terms (Exhibit 10.1): $500,000 annual base salary, discretionary bonus targeted at 75% of salary, and 700,000 stock options鈥�225,000 vesting over four years and 475,000 vesting on performance milestones. No family relationships or related-party transactions were reported.
Current CEO Ronnie Morris, M.D., will move to Executive Chairman to support the transition; Chairman Joel Ackerman will resume duties as Board Director. Related press release is filed as Exhibit 99.1.
Champions Oncology (CSBR) ha presentato un modulo 8-K comunicando un cambio di leadership con effetto dal 25 agosto 2025. Il direttore Robert Brainin, 54 anni, assumer脿 il ruolo di Amministratore Delegato mantenendo il suo posto nel consiglio di amministrazione. Brainin vanta oltre 25 anni di esperienza nel settore delle scienze della vita, pi霉 recentemente come Chief Business Officer e EVP presso Veracyte, e ha ricoperto ruoli dirigenziali in Genuity Science, Illumina, Thermo Fisher e Life Technologies.
Termini chiave dell'impiego (Allegato 10.1): stipendio base annuo di 500.000 dollari, bonus discrezionale con obiettivo pari al 75% dello stipendio e 700.000 opzioni azionarie鈥�225.000 con maturazione in quattro anni e 475.000 legate al raggiungimento di obiettivi di performance. Non sono state segnalate relazioni familiari o transazioni con parti correlate.
L'attuale CEO, Ronnie Morris, M.D., assumer脿 il ruolo di Presidente Esecutivo per supportare la transizione; il Presidente Joel Ackerman riprender脿 le funzioni di membro del Consiglio di Amministrazione. Il comunicato stampa correlato 猫 stato depositato come Allegato 99.1.
Champions Oncology (CSBR) present贸 un formulario 8-K anunciando un cambio de liderazgo efectivo a partir del 25 de agosto de 2025. El director Robert Brainin, de 54 a帽os, asumir谩 el cargo de Director Ejecutivo conservando su puesto en la junta directiva. Brainin aporta m谩s de 25 a帽os de experiencia en ciencias de la vida, recientemente como Chief Business Officer y EVP en Veracyte, y anteriormente desempe帽贸 cargos senior en Genuity Science, Illumina, Thermo Fisher y Life Technologies.
T茅rminos clave del empleo (Anexo 10.1): salario base anual de 500,000 d贸lares, bono discrecional con objetivo del 75% del salario y 700,000 opciones sobre acciones鈥�225,000 con consolidaci贸n en cuatro a帽os y 475,000 condicionadas a hitos de desempe帽o. No se reportaron relaciones familiares ni transacciones con partes relacionadas.
El actual CEO, Ronnie Morris, M.D., pasar谩 a ser Presidente Ejecutivo para apoyar la transici贸n; el Presidente Joel Ackerman retomar谩 sus funciones como Director de la Junta. El comunicado de prensa relacionado se present贸 como Anexo 99.1.
Champions Oncology (CSBR)電� 2025雲� 8鞗� 25鞚茧秬韯� 氚滍毃霅橂姅 毽崝鞁� 氤�瓴� 靷暛鞚� 瓿店皽頃橂姅 8-K 氤搓碃靹滊ゼ 鞝滌稖頄堨姷雼堧嫟. 鞚挫偓鞚� 搿滊矂韸� 敫岆爤鞚胳澑(54靹�)鞚� 鞚挫偓須� 鞛愲Μ毳� 鞙犾頃橂┐靹� 斓滉碃瓴届榿鞛�(CEO)搿� 鞛勲獏霅╇媹雼�. 敫岆爤鞚胳澑鞚� 25雲� 鞚挫儊鞚� 靸濍獏瓿柬暀 攵勳暭 瓴巾棙鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 斓滉芳鞐愲姅 Veracyte鞐愳劀 斓滉碃靷梾毂呾瀯鞛�(CBO) 瓴� EVP搿� 攴茧頄堨溂氅�, 鞚挫爠鞐愲姅 Genuity Science, Illumina, Thermo Fisher, Life Technologies鞐愳劀 瓿犾渼歆侅潉 鞐瀯頄堨姷雼堧嫟.
欤检殧 瓿犾毄 臁瓣贝(觳秬氍胳劀 10.1): 鞐瓣皠 旮半掣旮� 500,000雼煬, 旮夓棳鞚� 75%毳� 氇╉憸搿� 頃橂姅 鞛焿 氤措剤鞀�, 700,000欤� 欤检嫕 鞓奠厴鈥�225,000欤茧姅 4雲勳棎 瓯胳硱 氩犾姢韺呺悩氅� 475,000欤茧姅 靹标臣 氇╉憸 雼劚 鞁� 氩犾姢韺呺惄雼堧嫟. 臧�臁� 甏�瓿勲倶 甏�霠� 雼轨偓鞛� 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
順� CEO鞚� 搿滊媹 氇Μ鞀� 氚曥偓電� 鞝勴櫂 歆�鞗愳潉 鞙勴暣 歆戫枆 鞚橃灔(Executive Chairman)鞙茧 鞚措彊頃橂┌, 鞚橃灔鞚� 臁办棙 鞎犾护毹检潃 鞚挫偓須� 鞚挫偓 鞐呺毳� 鞛皽頃� 鞓堨爼鞛呺媹雼�. 甏�霠� 氤措弰鞛愲電� 觳秬氍胳劀 99.1搿� 鞝滌稖霅橃棃鞀惦媹雼�.
Champions Oncology (CSBR) a d茅pos茅 un formulaire 8-K annon莽ant un changement de direction effectif 脿 partir du 25 ao没t 2025. Le directeur Robert Brainin, 54 ans, deviendra le Directeur G茅n茅ral tout en conservant son si猫ge au conseil d'administration. Brainin poss猫de plus de 25 ans d'exp茅rience dans les sciences de la vie, ayant r茅cemment occup茅 le poste de Chief Business Officer et EVP chez Veracyte, et pr茅c茅demment exerc茅 des fonctions de direction chez Genuity Science, Illumina, Thermo Fisher et Life Technologies.
Principaux termes d'emploi (Annexe 10.1) : salaire de base annuel de 500 000 dollars, prime discr茅tionnaire cibl茅e 脿 75 % du salaire, et 700 000 options d'achat d'actions 鈥� 225 000 acquises sur quatre ans et 475 000 conditionn茅es 脿 des objectifs de performance. Aucune relation familiale ni transaction avec des parties li茅es n'a 茅t茅 signal茅e.
Le PDG actuel, Ronnie Morris, M.D., deviendra Pr茅sident ex茅cutif pour accompagner la transition ; le Pr茅sident Joel Ackerman reprendra ses fonctions de membre du conseil d'administration. Le communiqu茅 de presse associ茅 est d茅pos茅 en tant qu'Annexe 99.1.
Champions Oncology (CSBR) hat einen 8-K-Bericht eingereicht, der eine F眉hrungs盲nderung mit Wirkung zum 25. August 2025 bekannt gibt. Direktor Robert Brainin, 54 Jahre alt, wird Chief Executive Officer und beh盲lt gleichzeitig seinen Sitz im Vorstand. Brainin verf眉gt 眉ber mehr als 25 Jahre Erfahrung im Bereich Life Sciences, zuletzt als Chief Business Officer & EVP bei Veracyte, zuvor hatte er leitende Positionen bei Genuity Science, Illumina, Thermo Fisher und Life Technologies inne.
Wesentliche Besch盲ftigungsbedingungen (Anlage 10.1): Jahresgrundgehalt von 500.000 USD, ein diskretion盲rer Bonus mit Ziel von 75 % des Gehalts sowie 700.000 Aktienoptionen 鈥� 225.000 mit einer vierj盲hrigen Vesting-Periode und 475.000 abh盲ngig von Leistungserfolgen. Es wurden keine famili盲ren Beziehungen oder Transaktionen mit verbundenen Parteien gemeldet.
Der derzeitige CEO Ronnie Morris, M.D., wird zum Executive Chairman wechseln, um den 脺bergang zu unterst眉tzen; Vorsitzender Joel Ackerman wird seine Aufgaben als Vorstandsmitglied wieder aufnehmen. Die zugeh枚rige Pressemitteilung ist als Anlage 99.1 eingereicht.
- Appointment of industry veteran Robert Brainin as CEO brings 25+ years of oncology diagnostics and genomics expertise.
- Structured transition keeps outgoing CEO Ronnie Morris as Executive Chairman, preserving strategic continuity.
- Grant of 700,000 stock options could dilute existing shareholders if fully vested.
- Leadership change introduces execution risk during the handover period.
Insights
TL;DR: Routine but orderly CEO succession; governance structure preserved; compensation sizeable yet performance-weighted.
The company followed best-practice disclosure by filing the employment agreement and detailing option tranches. Retaining Morris as Executive Chairman ensures continuity and reduces strategic disruption risk. Compensation aligns cash and equity with shareholder value creation through performance-based vesting. Dilution is a consideration, but the staged vesting mitigates immediate impact. Overall, the move appears neutral from a governance risk perspective.
TL;DR: Hiring seasoned genomics executive could accelerate CSBR鈥檚 commercialization and partnering prospects, a strategically positive shift.
Brainin鈥檚 track record at Veracyte, Illumina and Thermo Fisher shows deep commercial expertise in oncology diagnostics and genomics services鈥攁reas core to Champions鈥� PDX and data-driven offerings. His network and operational know-how should enhance business development and broaden the client base. With Morris still engaged, institutional knowledge is retained. Execution will dictate value creation, but the appointment is directionally positive.
Champions Oncology (CSBR) ha presentato un modulo 8-K comunicando un cambio di leadership con effetto dal 25 agosto 2025. Il direttore Robert Brainin, 54 anni, assumer脿 il ruolo di Amministratore Delegato mantenendo il suo posto nel consiglio di amministrazione. Brainin vanta oltre 25 anni di esperienza nel settore delle scienze della vita, pi霉 recentemente come Chief Business Officer e EVP presso Veracyte, e ha ricoperto ruoli dirigenziali in Genuity Science, Illumina, Thermo Fisher e Life Technologies.
Termini chiave dell'impiego (Allegato 10.1): stipendio base annuo di 500.000 dollari, bonus discrezionale con obiettivo pari al 75% dello stipendio e 700.000 opzioni azionarie鈥�225.000 con maturazione in quattro anni e 475.000 legate al raggiungimento di obiettivi di performance. Non sono state segnalate relazioni familiari o transazioni con parti correlate.
L'attuale CEO, Ronnie Morris, M.D., assumer脿 il ruolo di Presidente Esecutivo per supportare la transizione; il Presidente Joel Ackerman riprender脿 le funzioni di membro del Consiglio di Amministrazione. Il comunicato stampa correlato 猫 stato depositato come Allegato 99.1.
Champions Oncology (CSBR) present贸 un formulario 8-K anunciando un cambio de liderazgo efectivo a partir del 25 de agosto de 2025. El director Robert Brainin, de 54 a帽os, asumir谩 el cargo de Director Ejecutivo conservando su puesto en la junta directiva. Brainin aporta m谩s de 25 a帽os de experiencia en ciencias de la vida, recientemente como Chief Business Officer y EVP en Veracyte, y anteriormente desempe帽贸 cargos senior en Genuity Science, Illumina, Thermo Fisher y Life Technologies.
T茅rminos clave del empleo (Anexo 10.1): salario base anual de 500,000 d贸lares, bono discrecional con objetivo del 75% del salario y 700,000 opciones sobre acciones鈥�225,000 con consolidaci贸n en cuatro a帽os y 475,000 condicionadas a hitos de desempe帽o. No se reportaron relaciones familiares ni transacciones con partes relacionadas.
El actual CEO, Ronnie Morris, M.D., pasar谩 a ser Presidente Ejecutivo para apoyar la transici贸n; el Presidente Joel Ackerman retomar谩 sus funciones como Director de la Junta. El comunicado de prensa relacionado se present贸 como Anexo 99.1.
Champions Oncology (CSBR)電� 2025雲� 8鞗� 25鞚茧秬韯� 氚滍毃霅橂姅 毽崝鞁� 氤�瓴� 靷暛鞚� 瓿店皽頃橂姅 8-K 氤搓碃靹滊ゼ 鞝滌稖頄堨姷雼堧嫟. 鞚挫偓鞚� 搿滊矂韸� 敫岆爤鞚胳澑(54靹�)鞚� 鞚挫偓須� 鞛愲Μ毳� 鞙犾頃橂┐靹� 斓滉碃瓴届榿鞛�(CEO)搿� 鞛勲獏霅╇媹雼�. 敫岆爤鞚胳澑鞚� 25雲� 鞚挫儊鞚� 靸濍獏瓿柬暀 攵勳暭 瓴巾棙鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 斓滉芳鞐愲姅 Veracyte鞐愳劀 斓滉碃靷梾毂呾瀯鞛�(CBO) 瓴� EVP搿� 攴茧頄堨溂氅�, 鞚挫爠鞐愲姅 Genuity Science, Illumina, Thermo Fisher, Life Technologies鞐愳劀 瓿犾渼歆侅潉 鞐瀯頄堨姷雼堧嫟.
欤检殧 瓿犾毄 臁瓣贝(觳秬氍胳劀 10.1): 鞐瓣皠 旮半掣旮� 500,000雼煬, 旮夓棳鞚� 75%毳� 氇╉憸搿� 頃橂姅 鞛焿 氤措剤鞀�, 700,000欤� 欤检嫕 鞓奠厴鈥�225,000欤茧姅 4雲勳棎 瓯胳硱 氩犾姢韺呺悩氅� 475,000欤茧姅 靹标臣 氇╉憸 雼劚 鞁� 氩犾姢韺呺惄雼堧嫟. 臧�臁� 甏�瓿勲倶 甏�霠� 雼轨偓鞛� 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
順� CEO鞚� 搿滊媹 氇Μ鞀� 氚曥偓電� 鞝勴櫂 歆�鞗愳潉 鞙勴暣 歆戫枆 鞚橃灔(Executive Chairman)鞙茧 鞚措彊頃橂┌, 鞚橃灔鞚� 臁办棙 鞎犾护毹检潃 鞚挫偓須� 鞚挫偓 鞐呺毳� 鞛皽頃� 鞓堨爼鞛呺媹雼�. 甏�霠� 氤措弰鞛愲電� 觳秬氍胳劀 99.1搿� 鞝滌稖霅橃棃鞀惦媹雼�.
Champions Oncology (CSBR) a d茅pos茅 un formulaire 8-K annon莽ant un changement de direction effectif 脿 partir du 25 ao没t 2025. Le directeur Robert Brainin, 54 ans, deviendra le Directeur G茅n茅ral tout en conservant son si猫ge au conseil d'administration. Brainin poss猫de plus de 25 ans d'exp茅rience dans les sciences de la vie, ayant r茅cemment occup茅 le poste de Chief Business Officer et EVP chez Veracyte, et pr茅c茅demment exerc茅 des fonctions de direction chez Genuity Science, Illumina, Thermo Fisher et Life Technologies.
Principaux termes d'emploi (Annexe 10.1) : salaire de base annuel de 500 000 dollars, prime discr茅tionnaire cibl茅e 脿 75 % du salaire, et 700 000 options d'achat d'actions 鈥� 225 000 acquises sur quatre ans et 475 000 conditionn茅es 脿 des objectifs de performance. Aucune relation familiale ni transaction avec des parties li茅es n'a 茅t茅 signal茅e.
Le PDG actuel, Ronnie Morris, M.D., deviendra Pr茅sident ex茅cutif pour accompagner la transition ; le Pr茅sident Joel Ackerman reprendra ses fonctions de membre du conseil d'administration. Le communiqu茅 de presse associ茅 est d茅pos茅 en tant qu'Annexe 99.1.
Champions Oncology (CSBR) hat einen 8-K-Bericht eingereicht, der eine F眉hrungs盲nderung mit Wirkung zum 25. August 2025 bekannt gibt. Direktor Robert Brainin, 54 Jahre alt, wird Chief Executive Officer und beh盲lt gleichzeitig seinen Sitz im Vorstand. Brainin verf眉gt 眉ber mehr als 25 Jahre Erfahrung im Bereich Life Sciences, zuletzt als Chief Business Officer & EVP bei Veracyte, zuvor hatte er leitende Positionen bei Genuity Science, Illumina, Thermo Fisher und Life Technologies inne.
Wesentliche Besch盲ftigungsbedingungen (Anlage 10.1): Jahresgrundgehalt von 500.000 USD, ein diskretion盲rer Bonus mit Ziel von 75 % des Gehalts sowie 700.000 Aktienoptionen 鈥� 225.000 mit einer vierj盲hrigen Vesting-Periode und 475.000 abh盲ngig von Leistungserfolgen. Es wurden keine famili盲ren Beziehungen oder Transaktionen mit verbundenen Parteien gemeldet.
Der derzeitige CEO Ronnie Morris, M.D., wird zum Executive Chairman wechseln, um den 脺bergang zu unterst眉tzen; Vorsitzender Joel Ackerman wird seine Aufgaben als Vorstandsmitglied wieder aufnehmen. Die zugeh枚rige Pressemitteilung ist als Anlage 99.1 eingereicht.
FAQ
When will Robert Brainin become CEO of CSBR?
What is Robert Brainin鈥檚 compensation package at Champions Oncology?
What role will current CEO Ronnie Morris take after the transition?
Are there any related-party transactions with the new CEO?
How are the 700,000 options structured?
